CRISPR gene therapy could free kids with thalassemia from lifelong blood transfusions

NCT ID NCT05356195

First seen Oct 31, 2025 · Last updated Jun 09, 2026 · Updated 30 times

Summary

This study tests a one-time gene therapy (CTX001) in 16 children with transfusion-dependent beta-thalassemia, a severe blood disorder requiring regular transfusions. The treatment uses CRISPR to modify the child's own blood stem cells so they produce healthy red blood cells. The main goal is to see if children can go without transfusions for at least 12 months. While not a cure (lifelong monitoring is needed), it aims to greatly reduce or eliminate the need for transfusions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOGLOBINOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Great Ormond Street Hospital for Children

    London, United Kingdom

  • Hospital for Sick Children - Hematology

    Toronto, Canada

  • IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica

    Rome, Italy

  • St.Mary's Hospital - Children's Clinical Research Facility

    London, United Kingdom

  • TriStar Medical Group Children's Specialists - Pediatric Oncology

    Nashville, Tennessee, 37203, United States

  • University Hospital Dusseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology

    Düsseldorf, Germany

Conditions

Explore the condition pages connected to this study.